WHICH PATIENTS WILL BENEFIT MOST FROM DOCETAXEL ADDITION TO ANDROGEN DEPRIVATION THERAPY (ADT) IN METASTATIC CASTRATE-SENSITIVE PROSTATE CANCER (MCSPC)?

Docetaxel improved the outcome of patients with mCSPC and became standard of care after CHAARTED, STAMPEDE arm C and GETUG-AFU 15 clinical trials and after subsequent meta-analysis. Patients with high-volume (CHAARTED definition) and high-risk (LATITUDE definition) disease, who have good performance...

Descripción completa

Detalles Bibliográficos
Autores principales: Gamulin, Marija, Bebek, Marko, Gnjidic, Milena
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Sestre Milosrdnice University Hospital and Institute of Clinical Medical Research, Vinogradska cesta c. 29 Zagreb 2019
Materias:
Professional Papers
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8693549/
https://www.ncbi.nlm.nih.gov/pubmed/34975202
http://dx.doi.org/10.20471/acc.2019.58.s2.12

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8693549/
https://www.ncbi.nlm.nih.gov/pubmed/34975202
http://dx.doi.org/10.20471/acc.2019.58.s2.12

Ejemplares similares